←
BioSpace38,557 posts
BioSpace avatar

BioSpace

@biospace

Your source for biopharma news and jobs

◷ Joined February 2009▧ 7,081 Photos and videos
BioSpace avatar
BioSpace@biospace·12m

Summit Therapeutics was warned twice by the FDA that the Phase 3 trial used to support the application for ivonescimab did not include patients that accurately represented the American population. hubs.li/Q04FFDn40

BioSpace avatar
BioSpace@biospace·1h

Acquiring a biotech with an existing Big Pharma partner can impose financial and strategic constraints around data sharing and milestone and royalty payments—but it is “rarely a deal-breaker,” according to one biotech consultant. hubs.li/Q04FFcGn0

BioSpace avatar
BioSpace@biospace·1h

The FDA declined to approve Summit Therapeutics’ Akeso-partnered ivonescimab, putting PD-1/VEGF developers on notice; Isomorphic raised a $5B series C, largest in biotech history; ObesityWeek & Clinical Trials on Alzheimer’s Disease conferences underway. hubs.li/Q04FFc4J0

BioSpace avatar
BioSpace@biospace·23h

Analysts are broadly confident that povetacicept will notch an approval in IgA nephropathy by the end of the month, setting up “the next wave” for Vertex Pharmaceuticals. hubs.li/Q04FwvVr0

BioSpace avatar
BioSpace@biospace·23h

At the 2026 Clinical Trials on Alzheimer’s Disease conference, AriBio reported that AR1001 slowed cognitive decline more than placebo in patients not taking other drugs for the disease. hubs.li/Q04Fv_gF0

BioSpace avatar
BioSpace@biospace·Nov 17

Sellas Life Sciences’ investigational cancer vaccine prolonged median overall survival by over nine months compared to standard of care in a Phase 3 trial for difficult-to-treat acute myeloid leukemia. hubs.li/Q04FvR120

BioSpace avatar
BioSpace@biospace·Nov 17

It’s been a long road to financial stability for Genetix Biotherapeutics, the rebranded name of bluebird bio following its February 2025 sale to two private equity firms, but on Monday the biotech estimated full year 2026 sales will reach $500 million. hubs.li/Q04FtYMD0

BioSpace avatar
BioSpace@biospace·Nov 16

Helus Pharma’s psilocin-based HLP003 significantly reduced symptoms of major depressive disorder in the adjuvant setting in a Phase 3 trial but was tripped up in the stock market by three serious adverse events. hubs.li/Q04FmGJ60